• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail
-

Search Publications



Fields



Centers











Starting Date


Ending Date


Order by

Entry Details

J Clin Invest 2017 Jun 30;127(7):2626-30

Glutamine supplementation suppresses herpes simplex virus reactivation.

Wang K, Hoshino Y, Dowdell K, Bosch-Marce M, Myers TG, Sarmiento M, Pesnicak L, Krause PR, Cohen JI

Abstract

Chronic viral infections are difficult to treat, and new approaches are needed, particularly those aimed at reducing reactivation by enhancing immune responses. Herpes simplex virus (HSV) establishes latency and reactivates frequently, and breakthrough reactivation can occur despite suppressive antiviral therapy. Virus-specific T cells are important to control HSV, and proliferation of activated T cells requires increased metabolism of glutamine. Here, we found that supplementation with oral glutamine reduced virus reactivation in latently HSV-1-infected mice and HSV-2-infected guinea pigs. Transcriptome analysis of trigeminal ganglia from latently HSV-1-infected, glutamine-treated WT mice showed upregulation of several IFN-gamma-inducible genes. In contrast to WT mice, supplemental glutamine was ineffective in reducing the rate of HSV-1 reactivation in latently HSV-1-infected IFN-gamma-KO mice. Mice treated with glutamine also had higher numbers of HSV-specific IFN-gamma-producing CD8 T cells in latently infected ganglia. Thus, glutamine may enhance the IFN-gamma-associated immune response and reduce the rate of reactivation of latent virus infection.


Category: Journal Article
PubMed ID: #28581445 DOI: 10.1172/JCI88990
PubMed Central ID: #PMC5490748
Includes FDA Authors from Scientific Area(s): Biologics
Entry Created: 2017-06-11 Entry Last Modified: 2017-07-25
Feedback
-
-